Related content

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

By Alba Emilio   Ruiz-Borrego Manuel   Margelí Mireia   Rodríguez-Lescure Álvaro   Sánchez-Rovira Pedro   Ruiz Amparo   Mel-Lorenzo Jose   Ramos-Vázquez Manuel   Ribelles Nuria   Calvo Elisa   Casado Antonio   Márquez Antonia   Vicente David   García-Sáenz José   Martín Miguel  

Breast Cancer Research and Treatment, Vol. 122, Iss. 1, 2010-07 ,pp. : 169-176

Springer Publishing Company

Access to resources Recommend Favorite

Effect of the dual phosphatidylinositol 3kinase/mammalian target of rapamycin inhibitor NVPBEZ235 against human Merkel cell carcinoma MKL1 cells

By          

Oncology Letters, Vol. 10, Iss. 6, 2015-01 ,pp. : 3663-3667

Spandidos Publications

Access to resources Recommend Favorite

Sarcomatoid renal cell carcinoma - basic biology, clinical behavior and response to therapy

By Chao D.   Zisman A.   Freedland S.J.   Pantuck A.J.   Said J.W.   Belldegrun A.S.  

Urologic Oncology: Seminars and Original Investigations, Vol. 6, Iss. 6, 2001-11 ,pp. : 231-238

Elsevier

Access to resources Recommend Favorite

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma

By Xu Zi-Zhen   Wang Wen-Fang   Fu Wan-Bin   Wang Ai-Hua   Liu Zhi-Yin   Chen Li-Yun   Guo Pei   Li Jun-Min  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1151-1157

Informa Healthcare

Access to resources Recommend Favorite